Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates

AIDS

Volumn 18, Issue 13, 2004, Pages 1787-1794

  Sista, Prakash R ^a,d   Melby, Tom ^a   Davison, Donna ^a   Jin, Lei ^a   Mosier, Sarah ^a   Mink, Mike ^a   Nelson, Emily L ^a   DeMasi, Ralph ^a   Cammack, Nick ^b   Salgo, Miklos P ^c   Matthews, Tom J ^a   Greenberg, Michael L ^a  

^a Trimeris Inc   (United States)

^b ROCHE BIOSCIENCE   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d BAYER CORPORATION   (United States)

Author keywords

Enfuvirtide; Fusion inhibition; gp41; Heptad repeat; Resistance testing; T 20

Indexed keywords

ANTIRETROVIRUS AGENT; ENFUVIRTIDE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS ISOLATION;

ADULT; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; PEPTIDE FRAGMENTS; PHENOTYPE;

EID: 4444310448     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200409030-00007     Document Type: Article

References (30)

1. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-1730.
2. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135:17-26.
3. Vittinghoff E, Scheer S, O'Malley P, Colfax C, Holmberg SD, Buchbinder SP. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999; 179:717-720.
4. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004; 350:1023-1035.
5. DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5:41-48.
6. Furuta RA, Wild CT, Weng Y, Weiss CD. Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol 1998; 5:276-279.
7. Weissenhorn W, Dessen A, Harrison SQ Skehel JJ, Wiley DC. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997; 387:426-430.
8. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994; 91:9770-9774.
9. Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 1998; 72:986-993.
10. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-2185.
11. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-2195.
12. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L, et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 2000; 74:8358-8367.
13. Derdeyn CA, Decker JM, Sfakianos JN, Zhang Z, O'Brien WA, Ratner L, et al. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol 2001; 75:8605-8614.
14. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46:1896-1905.
15. Mink M, Greenberg ML, Mosier S, Janumpalli S, Davison D, Jin L. Impact of HIV-1 gp41 amino acid substitutions (positions 36-45) on susceptibility to T-20 (enfuvirtide) in vitro: analysis of primary virus isolates recovered from patients during chronic enfuvirtide treatment and site directed mutants in NL4-3. Sixth International Workshop on Drug Resistance and Treatment Strategies, Seville, Spain, July 2002 [abstract 22].
16. Ratner L, Fisher A, Jagodzinski LL, Mitsuya H, Liou RS, Gallo RC, et al. Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res Hum Retroviruses 1987; 3:57-69.
17. Kimpton J, Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol 1992; 66:2232-2239.
18. Chackerian B, Long EM, Luciw PA, Overbaugh J. Human immunodeficiency virus type 1 coreceptors participate in post-entry stages in the virus replication cycle and function in simian immunodeficiency virus infection. J Virol 1997; 71:3932-3939.
19. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 2003; 27:493-497.
20. Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002; 18:685-693.
21. Melby T, Sista P, Nelson E, Mosier S, Mink M, Greenberg ML. Virological characterisation of patients through 48 weeks in T20-205 who acquired T-20 (enfuvirtide) resistance associated mutations during prior short-term enfuvirtide monotherapy. Sixth International Workshop on Drug Resistance and Treatment Strategies, Seville, Spain, July 2002 [abstract 70].
22. Wheeler DA, Lalezari JP, Kilby JM, Wheat I, Delehanty J, DeMasi R, et al. Safety, tolerability and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients. J Clin Virol 2003, 30:183-190.
23. Katlama C, Arastéh K, Clotet B, Cooper D, Henry K, Lalezari J, et al. Enfuvirtide TORO studies: 48 week results confirm 24 week findings. Second International AIDS Society meeting, Paris, France, July 2003 [abstract LB02].
24. Hanna SL, Yang C, Owen SM, Lal RB. Variability of critical epitopes within HIV-1 heptad repeat domains for selected entry inhibitors in HIV-infected populations worldwide [corrected]. AIDS 2002; 16:1603-1608.
25. Roman F, Gonzalez D, Lambert C, Deroo S, Fischer A, Baurith T, et al. Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains. J Acquir Immune Defic Syndr 2003; 33:134-139.
26. Greenberg ML, McDanal CB, Stanfield-Oakley SA, Jin L, Tremblay C, Sista P, et al. Virus sensitivity to T-20 and T-1249 is independent of coreceptor usage. Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, USA, February 2001 [abstract 473].
27. Stanfield-Oakley SA, Jeffrey J, McDanal CB, Mosier S, Talton L, Jin L, et al. Determinants of susceptibility to enfuvirtide map to gp41 in enfuvirtide-naive HIV-1. XII International HIV Drug Resistance Workshop, Los Cabos, Mexico, June 2003 [abstract 56].
28. Heil M, Decker JM, Chen J, Sfakianes J, Shaw G, Hunter E, et al. Analysis of patient-derived HIV-1 isolates suggests a novel mechanism for decreased sensitivity to inhibition by enfuvirtide and T-649. Second International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, France, July 2003 [abstract 801].
29. Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC, et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 2003; 17:691-698.
30. Lalezari J, DeJesus E, Northfelt D, Wolfe P., Haubrich R, Henry D. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir Ther 2003; 8:279-287.